



... **N E W S** and Information ... **N E W S** and Information
FOR IMMEDIATE RELEASE Contact: Ginya Carnahan (941)957-1221 • (877)328-8654

**LONGEST DATA, BEST CURE PROSTATE CANCER STUDY
ACCEPTED FOR PRESENTATION AT PRESTIGIOUS MEETING**

(December 16, 2008 – Sarasota, FL) **Dr. Michael Dattoli**, founder and physician-in-chief of the Dattoli Cancer Center & Brachytherapy Research Institute in Sarasota, has been notified that his research abstract, ***“Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease treated with brachytherapy and supplemental conformal radiation,”*** has been accepted for presentation at the American Society of Clinical Oncology’s Genitourinary Cancer Symposium February 2009, in Orlando.

The abstract presents findings of the largest and longest-standing study of patients with high-risk disease treated non-surgically with the combination of external radiation and radioactive seed implant.

Despite the negative indicators of the high-risk disease, and treatment that employed technology now 18 years old, an impressive 82% of these men remain disease-free after 16 years. The study gives credence to the trend away from surgical removal of the prostate gland as the “gold standard” treatment for this disease.

“Even for patients with the worst disease profiles, combination therapy in the hands of an expert has proven to offer far superior long-term results without the high incidence of negative, quality-of-life side effects (impotence and incontinence) often experienced after surgery – even supposedly *nerve-sparing* robotic surgery,” Dr. Dattoli concludes.

###